Product Description
An enzyme that breaks down a substance in the body called hyaluronic acid. Hyaluronic acid is found throughout the body in connective tissue, skin, and fluids in the joints and inside the eye. It causes fluids to have a jelly-like thickness, which can help moisten and protect tissues and joints. In medicine, hyaluronidase is made in the laboratory and given with other drugs by injection under the skin to treat certain conditions. Using hyaluronidase to break down hyaluronic acid helps make the fluids and connective tissue thinner so the drugs can move more easily into the tissues. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hyaluronidase)
Mechanisms of Action: Glycosaminoglycan Hydrolyzer
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Breast Cancer | Oncology Solid Tumor Unspecified | Oncology Unspecified
Known Adverse Events: Alopecia | Anemia | Neutropenia | Breast Cancer | Oncology Solid Tumor Unspecified | Oncology Unspecified | Asthenia | Diarrhea
Company: Halozyme
Company Location: SAN DIEGO CA 92121-1345
Company CEO: Helen I. Torley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Italy, Japan, Jordan, Kenya, Korea, Mexico, Netherlands, New Zealand, Oman, Poland, Romania, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Back Pain|Breast Cancer|Chronic Inflammatory Demyelinating Polyradiculoneuropathy|Deficiency Diseases|Edema|Non-Small-Cell Lung Cancer
Phase 2: Hodgkin Lymphoma|Lymphoma, B-Cell|Melanoma|Renal Cell Carcinoma
Phase 1: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Anemia, Aplastic|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Healthy Volunteers|Multiple Myeloma|Myelodysplastic Syndrome|Myelofibrosis|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Stem Cell Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TAK-881-3002 | P3 |
Unknown Status |
Deficiency Diseases |
2029-02-13 |
|
| WO44263 | P3 |
Unknown Status |
Breast Cancer |
2028-12-31 |
|
| MK-3475A-F65 | P2 |
Recruiting |
Hodgkin Lymphoma|Lymphoma, B-Cell |
2028-11-08 |
|
| DEMETHER | P2 |
Recruiting |
Breast Cancer |
2026-11-01 |